ArticleNeuro-oncology2015

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Jerrold L Boxerman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.